Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Cabaletta Bio, Inc.

35 indications, side-by-side phase, drug & LoA

$3.01

+0.01 (+0.33%)

C 40Pipeline Score Undervalued Biotech · Commercial
Market Cap
595.15 M
EPS
-1.97
P/E Ratio
-
Value Trade
16.70 M
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • R&D Expenses

    37.35 M

  • Operating CF

    -42.56 M

  • Total Assets

    148.15 M

  • Total Liabilities

    44.84 M

  • Equity

    103.31 M

  • D/E Ratio

    12,345

4.29 %
Week
14.78 %
1 Month
18.89 %
3 Month
68.2 %
6 Month
-67.5 %
5 Year
-59.44 %
All Time
Cash Data
Caution

  • Cash Position

    116.64 M

  • Monthly Burn

    14.19 M

  • Runway

    7.3 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
2.92 M
52 Week Range
1.26 - 4.23
% held by Insiders
12.43 %
% held by Institutions
55.41 %
Enterprise Value
504.97 M
Total Shares
111.31 M
Short %
21.79 %
Float Shares
105.30 M
Company Description
HQ: 2929 ARCH STREET, PHILADELPHIA...
Employees:158
https://www.cabalettabio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
BLA Filing example
BLA
—
Cell Therapies
Musculoskeletal System
BLA
—
Cell Therapies
Musculoskeletal System
BLA
—
Cell Therapies
Musculoskeletal System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C40
Pipeline Score
$614M
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
3.4x
rNPV / MCap
Top 54%
Micro Cap
(rank 417 of 905)
Percentile Rank
Cabaletta Bio, Inc. carries a moderate pipeline score (40/100), with $3.0B risk-adjusted pipeline value, led by CABA-201 in Relapsing Multiple Sclerosis (RMS) (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
CABA-201
Monoclonal antibody		Relapsing Multiple Sclerosis (RMS)Phase 1NCT0700680563% $2.7B NOT YET_RECRUITING 12 VERY_FAST D (38) Oct 1, 2029MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
rese-cel (resecabtagene autoleucel)
pemphigus vulgaris
Phase 1/2
2025-10-10
rese-cel (resecabtagene autoleucel)
pemphigus vulgaris
Phase 1/2
2025-10-10
rese-cel (resecabtagene autoleucel)
pemphigus vulgaris
Phase 1/2
2025-10-10
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CABA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CABA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CABA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CABA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CABA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CABA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Cabaletta Bio, Inc. (CABA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CABA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Autoimmune Disorders #6 of 10 PHASE 2 CABA-201 following preconditioning with fludarabine and cyclophosphamide
ARGX ROIV AZN
$25.4B 0.89 FOLLOWER
Lupus Nephritis #11 of 17 PHASE 1 CABA-201
NVS VTRS AZN
$1.2B 0.86 FOLLOWER
Multiple Sclerosis #16 of 20 PHASE 1 CABA-201
SNY NVS BIIB
$31.92B 0.88 FOLLOWER
Myasthenia Gravis #16 of 19 PHASE 1 CABA-201
ARGX AZN NVS
$2.18B 0.84 FOLLOWER
Systemic Sclerosis #17 of 21 PHASE 1 CABA-201
AZN BMY MRK
$2.68B 0.77 FOLLOWER
Systemic Lupus Erythematosus #22 of 32 PHASE 1 CABA-201
BIIB VTRS BMY
$2.78B 0.86 FOLLOWER
Rare Neurological Disorders #28 of 46 PHASE 2 CABA-201 following preconditioning with fludarabine and cyclophosphamide
IONS BIIB SRPT
$139.4B 0.89 FOLLOWER